MERCATOR MEDSYSTEMS, INC.
Emeryville, CA · CIK 0001355036 · Medtech · Private
Perivascular drug delivery system for local anti-inflammatory therapy during catheter-directed thrombolysis
mercatormed.com →- Grants
- $6.0M
- 6 awards
- Sector median: 1
- Raised
- $17M
- 2 Form D · Jul 2018
- 99 months since last filing
- Contracts
- $13K
- 1 award · Health and Human S
- #623 of 4531 in medtech
- Patents
- 40
- 20 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,209,674 | |
| Private capital raised | Form D · SEC | $11,153,376 | |
| Federal grant | Department of Health and Human Services · Phase I · Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery | $299,678 | |
| Federal contract | Department of Health and Human Services · Mercator Medsystems, INC.:1129327 [23-010141] Needles | $13,200 | |
| Federal grant | Department of Health and Human Services · Phase II · Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery | $1,636,379 | |
| Federal grant | Department of Health and Human Services · Phase II · Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease | $1,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Preventing Post-Thrombotic Syndrome after Deep Vein Thrombosis with Perivascular Anti-Inflammatory Agent Delivery | $1,095,555 | |
| Federal grant | Department of Health and Human Services · Phase II · Improved Sirolimus-Analog Adventitial Delivery to Enhance Outcomes in Below-the-Knee Peripheral Artery Disease | $1,000,000 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 620 | DAY ZERO DIAGNOSTICS INC | $14K | $2.5M |
| 621 | Sientra, Inc. | $14K | $65M |
| 622 | EnteroTrack, LLC | $13K | $4.9M |
| 623 | MERCATOR MEDSYSTEMS, INC. | $13K | $17M |
| 624 | VULINTUS, INC | $12K | — |
| 625 | Cortechs Labs, Inc. | $12K | $9.1M |
| 626 | MIYAZAKI ENTERPRISES LLC | $11K | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Stephen BakerExecutive Officer
- Charles CrockerDirector
- Neil DesaiDirector
- Joel KanterDirector
- Thomas LoarieDirector · Executive Officer
- Trent ReutimanDirector · Executive Officer
- Ned ScheetzDirector
- Kirk SewardDirector · Executive Officer
- Doug WallDirector
Patents
- Treatment Of Restenosis Using Temsirolimusapplication
- Treatment Of Hypertension By Renal Vascular Delivery Of Guanethidineapplication
- Combination Therapy For Treatment Of Restenosisapplication
- Combination Therapy For Treatment Of Restenosisgranted
- Medical Instrument And Medical Method For Localized Drug Deliveryapplication
- Medical Instrument And Medical Method For Localized Drug Deliverygranted
- Perivascular Anti-inflammatory Therapy For Venous Thrombosisapplication
- Treatment Of Restenosis Using Temsirolimusapplication
- Treatment Of Hypertension By Renal Vascular Delivery Of Guanethidineapplication
- Treatment Of Hypertension By Renal Vascular Delivery Of Guanethidinegranted
- Combination Therapy For Treatment Of Restenosisgranted
- Localized Modulation Of Tissues And Cells To Enhance Therapeutic Effects Including Renal Denervationgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.